The capital charge associated with private equity in the Solvency II directive could ultimately be lowered from the current 49% to 39%, unquote" understands.
Existing investors including Institut Català de Finances also take part in the financing
Biotech company initially raised €12m in December 2018
Amount includes the capital raised by Eurazeo Growth III, which has now collected more than €500m
Allan Marchington, who will become head of ICG life sciences, says the team has a strong pipeline